Moving iPSC-Derived Cardiomyocytes Forward to Treat Myocardial Infarction.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30193131.
- Also identified by DOI 10.1016/j.stem.2018.08.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human pluripotent stem cell-derived cardiomyocytes represent a promising cell source for cardiac repair. However, their clinical translation is hindered by limited evidence for functional benefits in primate models, potential risks for arrhythmias, and teratoma formation. A recent study by Liu et al. (2018) makes significant progress on these critical issues.
Medical subject headings
- Human Embryonic Stem Cells
- Induced Pluripotent Stem Cells
- Myocardial Infarction